SKYRIZI RESULTS
See How SKYRIZI Can Help You Achieve EARLY SYMPTOM RELIEF and TAKE CONTROL OF CROHN’S
HOW SOON CAN YOU FEEL SYMPTOM RELIEF?
Feel significant symptom
relief in as few as 4 weeks,
including less abdominal pain and fewer bowel movements.
WHEN CAN YOU EXPERIENCE REMISSION?
AT 12 WEEKS
44%*
of patients in two clinical trials experienced EARLY REMISSION
600 mg IV starter infusion†
At 12 weeks, some patients who achieved clinical response on SKYRIZI entered into a maintenance trial.‡
AT 1 YEAR
61%‡
of those who entered experienced LASTING REMISSION
180 mg SC maintenance injection§
And 57%‡ of those who entered experienced remission with the 360 mg SC maintenance injection.§
Your doctor will decide what maintenance dose is right for you.
In another trial, many people were in REMISSION EVEN AT 2 YEARS||
||In a less rigorous study at 2 years, physicians and patients knew that SKYRIZI was being used, which may have influenced results.
WHEN CAN YOUR DOCTOR SEE VISIBLE IMPROVEMENT OF INTESTINAL LINING DAMAGE?
AT 12 WEEKS
36%*
of patients in two clinical trials achieved VISIBLY IMPROVED DAMAGE OF THE INTESTINAL LINING
600 mg IV starter infusion†
At 12 weeks, some patients who achieved clinical response on SKYRIZI entered into a maintenance trial.‡
AT 1 YEAR
50%‡
of those who entered achieved
VISIBLY IMPROVED DAMAGE OF THE INTESTINAL LINING
180 mg SC maintenance injection§
And 48%‡ of those who entered achieved visibly improved damage of the intestinal lining with the 360 mg maintenance injection.§
Your doctor will decide what maintenance dose is right for you.
EVEN AT 1 YEAR, many people achieved little to no visible evidence of active Crohn’s‡¶
¶Based on areas that were assessed on endoscopy. In the clinical trial, this measure was not tested for a difference between SKYRIZI and placebo.
Individual results may vary.
*Results are combined from 2 clinical trials of 527 patients: one included patients with or without prior biologic failure and the other included patients with prior biologic failure.
†Intravenous infusion (through a vein in the arm).
‡Results from 252 patients who achieved clinical response defined as a reduction in CDAI of at least 100 points from baseline after 12 weeks of treatment with SKYRIZI.
§Subcutaneous injection (under the skin).
Real Patients, Real Results
Hear from Kade, a SKYRIZI patient, sharing his experience on symptom relief.
I started noticing results 4 weeks in.
Kade, a Crohn’s
patient using SKYRIZI
QUICK POLL
Up Next
Talk to your doctor about your symptoms and treatment options.
Recommended for You
Learn more about how SKYRIZI specifically targets the IL-23 protein.